Intravenous iron dextran for severe refractory restless legs syndrome

Sleep Medicine

Volumn 11, Issue 5, 2010, Pages 494-496

  Ondo, William G ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Dopamine; Intravenous iron; Iron; Refractory; Restless legs syndrome; Therapy

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; FERRITIN; IRON DEXTRAN;

ADULT; AGED; ANAPHYLAXIS; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFECT; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG SAFETY; FAMILY HISTORY; FEMALE; HUMAN; HYPOTENSION; MALE; MOLECULAR WEIGHT; NAUSEA; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; RETROSPECTIVE STUDY; SYMPTOM; TREATMENT RESPONSE; URTICARIA;

ADULT; AGED; ANAPHYLAXIS; BRAIN; DOPAMINE; DRUG RESISTANCE; FEMALE; HEMATINICS; HUMANS; INFUSIONS, INTRAVENOUS; IRON; IRON-DEXTRAN COMPLEX; MALE; MIDDLE AGED; RESTLESS LEGS SYNDROME; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77951651688     PISSN: 13899457     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sleep.2009.12.002     Document Type: Article

References (13)

1. Allen R.P., Picchietti D., Hening W.A., Trenkwalder C., Walters A.S., Montplaisi J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003, 4(2):101-119.
2. Winkelmann J., Schormair B., Lichtner P., et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet 2007, 39(8):1000-1006.
3. Schormair B., Kemlink D., Roeske D., et al. PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nat Genet 2008, 40(8):946-948.
4. Connor J.R. Pathophysiology of restless legs syndrome: evidence for iron involvement. Curr Neurol Neurosci Rep 2008, 8(2):162-166.
5. Connor J.R., Boyer P.J., Menzies S.L., et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology 2003, 61(3):304-309.
6. O'Keeffe S.T., Gavin K., Lavan J.N. Iron status and restless legs syndrome in the elderly. Age Ageing 1994, 23(3):200-203.
7. Nordlander N.B. Therapy in restless legs. Acta Med Scand 1953, 145(6):453-457.
8. Davis B.J., Rajput A., Rajput M.L., Aul E.A., Eichhorn G.R. A randomized, double-blind placebo-controlled trial of iron in restless legs syndrome. Eur Neurol 2000, 43(2):70-75.
9. Earley C.J., Heckler D., Allen R.P. Repeated IV doses of iron provides effective supplemental treatment of restless legs syndrome. Sleep Med 2005, 6(4):301-305.
10. Sloand J.A., Shelly M.A., Feigin A., Bernstein P., Monk R.D. A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis 2004, 43(4):663-670.
11. Grote L., Leissner L., Hedner J., Ulfberg J. A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Mov Disord 2009, 24(10):1445-1452.
12. Chertow G.M., Mason P.D., Vaage-Nilsen O., Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006, 21(2):378-382.
13. Earley C.J., Heckler D., Allen R.P. The treatment of restless legs syndrome with intravenous iron dextran. Sleep Med 2004, 5(3):231-235.